Exelixis Inc. (EXEL)
Last updated: 2026-10-21 00:52:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Exelixis Inc. (EXEL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $64.39, with a market capitalization of $15.42B and a P/E ratio of 18.05. Over the past 52 weeks, its price has ranged from $33.76 to $64.41. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$15.42B | |
$63.01 | |
$999.99 | |
$1.26 | |
$62.68 | |
1.65M | |
2.38M | |
18.05 | |
$64.41 | |
$33.76 | |
-- | |
-- |
Exelixis Inc. (EXEL) Latest Closing Stock Price
Exelixis Inc. (EXEL) last closed at $62.68 as of 2026-10-20 23:57:00, unchanged from the previous close of $62.68.
During the latest regular trading session, EXEL traded between $1.26 and $999.99, with a volume of 1.65M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Exelixis Inc. (EXEL) 7-Day Stock Price Change
Over the past seven days, Exelixis Inc. (EXEL) moved from $59.86 to $64.39, representing a gain of 7.57% ($4.53).
The stock traded between $58.59 and $64.41 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.65 million shares, up versus the previous seven-day period, indicating higher trading activity.
EXEL 52-Week Price Position
Position in Range: 100.0%
EXEL is currently trading at $64.39, placing it 100.0% of the way from its 52-week low of $33.76 to its 52-week high of $64.41. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Exelixis Inc. (EXEL)?
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 1077 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Exelixis Inc. (EXEL) Stock on MEXC
Eligible investors can buy real shares of Exelixis Inc. (EXEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Exelixis Inc. (EXEL) stock price today?
2.Is EXEL stock going up or down today?
3.What is EXEL pre-market price?
4.What is EXEL after-hours price?
5.Is EXEL stock trading now?
6.Where does EXEL sit relative to its 52-week high and low?
7.What sector is Exelixis Inc. in?
8.What is Exelixis Inc.'s market capitalization and where is it listed?
9.How is EXEL valued in terms of P/E ratio and EPS?
10.Does Exelixis Inc. pay a dividend?
Explore More US Stocks
Search Stocks
EXEL Stock Calculator
Estimate the value between EXEL shares and USD.
EXEL Shares to USD
1.00 EXEL shares = 64.39 USD
Calculations are estimates based on the latest available price and are for reference only.


